• Explore /
  • Poster
  • / Targeting <em>HER2</em> (<em>ERBB2</em>) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial.

Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial.

Abstract Video & Slides Poster

Authors

null

James J. Harding

Memorial Sloan Kettering Cancer Center, New York, NY

James J. Harding , James M. Cleary , David I. Quinn , Irene Braña , Victor Moreno , Mitesh J. Borad , Sherene Loi , Iben Spanggaard , Haeseong Park , James M. Ford , Monica Arnedos , Salomon M. Stemmer , Christelle De La Fouchardiere , Santiago Viteri Ramirez , Christos Fountzilas , Jie Zhang , Feng Xu , Alshad S. Lalani , Sarina Anne Piha-Paul , Ghassan K. Abou-Alfa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Hepatobiliary Cancer

Track

Hepatobiliary Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT01953926

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 320)

DOI

10.1200/JCO.2021.39.3_suppl.320

Abstract #

320

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: James J. Harding

First Author: Ahmad Awada

First Author: Zhen-gang Yuan

First Author: Do-Youn Oh